Actinogen Gains Positive Regulatory Support for Alzheimer’s Treatment Program
Actinogen Medical Limited (ASX: ACW) has received encouraging guidance from the European Medicines Agency (EMA) regarding the development of its Alzheimer’s treatment candidate, Xanamem. The feedback closely matches earlier recommendations provided by the US FDA, giving the company greater clarity on the pathway toward potential approvals in two major pharmaceutical markets.
The EMA supported the company’s manufacturing strategy and indicated that only one additional pivotal Phase 3 study may be needed following successful results from the ongoing XanaMIA trial. The regulator also recommended expanding patient eligibility to include individuals with moderate Alzheimer’s disease.
Actinogen expects topline results from the XanaMIA study in November 2026. Positive outcomes could strengthen future commercial opportunities and partnership discussions for Xanamem, which is designed to reduce harmful cortisol activity in the brain associated with Alzheimer’s disease progression.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Actinogen Gains Positive Regulatory Support for Alzheimer’s Treatment Program
Actinogen Medical Limited (ASX: ACW) has received encouraging guidance from the European Medicines Agency (EMA) regarding the development of its Alzheimer’s treatment candidate, Xanamem. The feedback closely matches earlier recommendations provided by the US FDA, giving the company greater clarity on the pathway toward potential approvals in two major pharmaceutical markets.
The EMA supported the company’s manufacturing strategy and indicated that only one additional pivotal Phase 3 study may be needed following successful results from the ongoing XanaMIA trial. The regulator also recommended expanding patient eligibility to include individuals with moderate Alzheimer’s disease.
Actinogen expects topline results from the XanaMIA study in November 2026. Positive outcomes could strengthen future commercial opportunities and partnership discussions for Xanamem, which is designed to reduce harmful cortisol activity in the brain associated with Alzheimer’s disease progression.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au